Have a personal or library account? Click to login
Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients Cover

Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients

Open Access
|Jan 2024

References

  1. Fine JD. Inherited epidermolysis bullosa. Orphanet J Rare Dis. 2010;5:12. http://doi.org/10.1186/1750-1172-5-12 PMid:20507631
  2. Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931-50. https://doi.org/10.1016/j.jaad.2008.02.004 PMid:18374450
  3. Intong LR, Murrell DF. Inherited epidermolysis bullosa: New diagnostic criteria and classification. Clin Dermatol. 2012;30(1):70-7. shttps://doi.org/10.1016/j.clindermatol.2011.03.012 PMid:22137229
  4. Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the national epidermolysis Bullosa registry. JAMA Dermatol. 2016;152(11):1231-8. https://doi.org/10.1001/jamadermatol.2016.2473 PMid:27463098
  5. Farokhforghani S, Fatemi MJ, Ghanooni P, Asadpour F, Araghi S, Nouri A. Epidermolysis bullosa registry data in Iran. World J Plast Surg. 2021;10(3):99-103. shttps://doi.org/10.29252/wjps.10.3.99 PMid:34912673
  6. Kho YC, Rhodes LM, Robertson SJ, Su J, Varigos G, Robertson I, et al. Epidemiology of epidermolysis bullosa in the antipodes: The Australasian Epidermolysis bullosa Registry with a focus on Herlitz junctional epidermolysis bullosa. Arch Dermatol. 2010;146(6):635-40. http://doi.org/10.1001/archdermatol.2010.109 PMid:20566927
  7. Petrof G, Papanikolaou M, Martinez AE, Mellerio JE, McGrath JA, Bardhan A, et al. The epidemiology of epidermolysis bullosa in England and Wales: Data from the national epidermolysis bullosa database. Br J Dermatol. 2022;186(5):843-8. https://doi.org/10.1111/bjd.20958 PMid:34927719
  8. Brandling-Bennett HA, Morel KD. Common wound colonizers in patients with epidermolysis bullosa. Pediatr Dermatol. 2010;27(1):25-8. https://doi.org/10.1111/j.1525-1470.2009.01070.x PMid:20199405
  9. Fatima Q, Ahmed N, Siddiqui B, Rehman A, Haq I, Khan GM, et al. Enhanced antimicrobial activity of silver sulfadiazine cosmetotherapeutic nanolotion for burn infections. Cosmetics. 2022;9(5):93.
  10. Liu X, Gan H, Hu C, Sun W, Zhu X, Meng Z, et al. Silver sulfadiazine nanosuspension-loaded thermosensitive hydrogel as a topical antibacterial agent. Int J Nanomedicine. 2019;14:289-300. https://doi.org/10.2147/IJN.S187918 PMid:30643407
  11. Nasiri E, Hosseinimehr SJ, Azadbakht M, Akbari J, Enayati-Fard R, Azizi S, et al. The healing effect of Arnebia euchroma ointment versus silver sulfadiazine on burn wounds in rat. World J Plast Surg. 2015;4(2):134-44.
  12. Ou YY, Jiang Y, Li H, Zhang YY, Lu Y, Chen DF. Polysaccharides from Arnebia euchroma ameliorated endotoxic fever and acute lung injury in rats through inhibiting complement system. Inflammation. 2017;40(1):275-84. https://doi.org/10.1007/s10753-016-0478-0 PMid:27913955
  13. Kumar A, Shashni S, Kumar P, Pant D, Singh A, Verma RK. Phytochemical constituents, distributions and traditional usages of Arnebia euchroma: A review. J Ethnopharmacol. 2021;271:113896. https://doi.org/10.1016/j.jep.2021.113896 PMid:33524510
  14. Jain R, Bhardwaj P, Pandey SS, Kumar S. Arnebia euchroma, a plant species of cold desert in the himalayas, harbors beneficial cultivable endophytes in roots and leaves. Front Microbiol. 2021;12:696667. https://doi.org/10.3389/fmicb.2021.696667 PMid:34335527
  15. Pourani MR, Vahidnezhad H, Mansouri P, Youssefian L, Rakhshan A, Hajimoradi B, et al. Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series. Dermatol Ther. 2022;35(7):e15515. http://doi.org/10.1111/dth.15515 PMid:35420725
  16. Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol. 2018;9:248. https://doi.org/10.3389/fimmu.2018.00248 PMid:29520266
  17. Sindici E, Astesano S, Fazio L, Dragonetti A, Pugliese M, Scully C, et al. Treatment of oral lesions in dystrophic epidermolysis bullosa: A case series of cord blood platelet gel and low-level laser therapy. Acta Derm Venereol. 2017;97(3):383-4. https://doi.org/10.2340/00015555-2512 PMid:27535037
  18. Rogers CL, Gibson M, Kern JS, Martin LK, Robertson SJ, Daniel BS, et al. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). JAAD Int. 2021;2:134-52. https://doi.org/10.1016/j.jdin.2020.12.007 PMid:34409361
  19. Jain SV, Harris AG, Su JC, Orchard D, Warren LJ, McManus H, et al. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): Grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2017;31(4):692-8. https://doi.org/10.1111/jdv.13953 PMid:27580431
  20. Yazdanshenas A, Naderi E, Moravvej H, Heidari K, Faghankhani M, Vahidnezhad H, et al. The quality of life in epidermolysis bullosa (EB-QoL) questionnaire: Translation, cultural adaptation, and validation into the Farsi language. Int J Womens Dermatol. 2020;6(4):301-5. https://doi.org/10.1016/j.ijwd.2020.05.012 PMid:33015291
  21. Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: An EB-specific quality of life instrument. Br J Dermatol. 2009;161(6):1323-30. https://doi.org/10.1111/j.1365-2133.2009.09347.x PMid:19681875
  22. Bardhan A, Bruckner-Tuderman L, Chapple IL, Fine JD, Harper N, Has C, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6(1):78. https://doi.org/10.1038/s41572-020-0210-0 PMid:32973163
  23. Kaith BS, Kaith NS, Chauhan NS. Anti-inflammatory effect of Arnebia euchroma root extracts in rats. J Ethnopharmacol. 1996;55(1):77-80. https://doi.org/10.1016/s0378-8741(96)01477-8 PMid:9121171
  24. Liu H, Jin YS, Song Y, Yang XN, Yang XW, Geng DS, et al. Three new compounds from Arnebia euchroma. J Asian Nat Prod Res. 2010;12(4):286-92. https://doi.org/10.1080/10286021003743861 PMid:20419539
  25. Shen CC, Syu WJ, Li SY, Lin CH, Lee GH, Sun CM. Antimicrobial activities of naphthazarins from Arnebia euchroma. J Nat Prod. 2002;65(12):1857-62. https://doi.org/10.1021/np010599w PMid:12502328
  26. Atiyeh BS, Costagliola M, Hayek SN, Dibo SA. Effect of silver on burn wound infection control and healing: Review of the literature. Burns. 2007;33(2):139-48. https://doi.org/10.1016/j.burns.2006.06.010 PMid:17137719
  27. Lu L, Qin A, Huang H, Zhou P, Zhang C, Liu N, et al. Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition. Eur J Pharmacol. 2011;658(2-3):242-7. https://doi.org/10.1016/j.ejphar.2011.02.043 PMid:21392503
  28. Sun WX, Liu Y, Zhou W, Li HW, Yang J, Chen ZB. Shikonin inhibits TNF-α production through suppressing PKC-NF-κB-dependent decrease of IL-10 in rheumatoid arthritis-like cell model. J Nat Med. 2017;71(2):349-56. https://doi.org/10.1007/s11418-016-1064-3 PMid:27943122
  29. Yan Y, Furumura M, Gouya T, Iwanaga A, Teye K, Numata S, et al. Shikonin promotes skin cell proliferation and inhibits nuclear factor-κb translocation via proteasome inhibition in vitro. Chin Med J (Engl). 2015;128(16):2228-33. https://doi.org/10.4103/0366-6999.162512 PMid:26265618
  30. Lee YS, Lee DY, Kim YB, Lee SW, Cha SW, Park HW, et al. The mechanism underlying the antibacterial activity of shikonin against methicillin-resistant Staphylococcus aureus. Evid Based Complement Alternat Med. 2015;2015:520578. https://doi.org/10.1155/2015/520578 PMid:26265924
  31. Li J, Li S, Li H, Guo X, Guo D, Yang Y, et al. Antibiofilm activity of shikonin against Listeria monocytogenes and inhibition of key virulence factors. Food Control. 2021;120(1):107558. https://doi.org/10.1016/j.foodcont.2020.107558
  32. Ahmad F, Bibi S, Kang M, Anees M, Ansar M, Alam MR, et al. Naphthoquinones from Handroanthus impetiginosus promote skin wound healing through Sirt3 regulation. Iran J Basic Med Sci. 2020;23(9):1139-45. http://doi.org/10.22038/ijbms.2020.43706.10275 PMid:32963735
  33. Soltanian AR, Mehdibarzi D, Faghihzadeh S, Naseri M, Gerami A. Mixture of Arnebia euchroma and Matricaria chamomilla (Marhame-Mafasel) for pain relief of osteoarthritis of the knee - a two-treatment, two-period crossover trial. Arch Med Sci. 2010;6(6):950-5. http://doi.org/10.5114/aoms.2010.19307 PMid:22427772
  34. Nasiri E, Hosseinimehr SJ, Hosseinzadeh AZ, Azadbakht M, Akbari J, Azadbakht M. The effects of Arnebia euchroma ointment on second-degree burn wounds: A randomized clinical trial. J Ethnopharmacol. 2016;189:107-16. http://doi.org/10.1016/j.jep.2016.05.029 PMid:27180881
  35. Memarbashi E, Nasiri E, Etezadpour M, Hosseinimehr SJ. Effect of Arnebia euchroma ointment on pain and burning after hemorrhoidectomy: A randomized clinical trial. J Mazandaran Univ Med Sci. 2021;31(202):38-48.
  36. Aliasl J, Khoshzaban F, Barikbin B, Naseri M, Kamalinejad M, Emadi F, et al. Comparing the healing effects of Arnebia euchroma Ointment with petrolatum on the ulcers caused by fractional CO2 laser: A single-blinded clinical trial. Iran Red Crescent Med J. 2014;16(10):e16239. https://doi.org/10.5812/ircmj.16239 PMid:25558382
Language: English
Page range: 56 - 61
Submitted on: Apr 28, 2023
Accepted on: Jul 3, 2023
Published on: Jan 3, 2024
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2024 Amirsaleh Abdollahi, Rouzbeh Kadkhodaee, Armaghan Kazeminejad, Lotfollah Davoodi, Muhammadreza Oraee Karimi, Alireza Razavi, Sobhan Mohebbi Najmabad, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.